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IntroductIon
Type 2, or allergic, inflammation in the lung requires the 
cytokines IL-5, IL-13, and IL-9, which collectively elicit 
eosinophilia, alternative activation of macrophages, gob-
let cell hyperplasia, smooth muscle hypercontractility, and 
tissue remodeling, and may contribute to wound healing 
(Licona-Limón et al., 2013; Gour and Wills-Karp, 2015). As 
long-lived tissue-resident cells, group 2 innate lymphoid cells 
(ILC2s) are a critical early source of these type 2 cytokines 
before type 2 helper T cell (Th2 cell) recruitment. The role of 
ILC2s in promoting type 2 lung inflammation has been es-
tablished in mice using models such as parasitic worm infec-
tion, chitin, papain, fungal, or house dust mite challenge, and 
allergic asthma (Neill et al., 2010; Price et al., 2010; Barlow et 
al., 2012; Bartemes et al., 2012; Halim et al., 2012; Klein Wol-
terink et al., 2012; Van Dyken et al., 2014). In humans, ILC2s 
accumulate in nasal polyps of patients with chronic sinusitis 
(Mjösberg et al., 2011; Ho et al., 2015), and genome-wide 
association studies have implicated the ILC2-activating cyto-
kine IL-33 in airways disease (Ober and Yao, 2011).
The mechanisms of ILC2 activation upon encounter of a 
type 2 agonist remain incompletely understood. Because Th2 
cells and ILC2s require the same transcription factors for their 
differentiation and secrete many of the same cytokines, our ex-
tensive understanding of gene regulation in Th2 cells may be 
informative for ILC2 biology. In Th2 cells, signaling through 
the TCR activates a phospholipase C (PLC)–dependent 
signaling cascade that drives three primary responses: 
(1) cytosolic Ca2+ influx, calcineurin activation, and trans-
location of NFAT into the nucleus, (2) MAPK-dependent 
translocation of activator protein 1 (AP-1) to the nucleus, and 
(3) protein kinase C (PKC)–dependent activation of NF-κB. 
In the nucleus, NFAT, AP-1, and NF-κB cooperatively drive 
expression of type 2 cytokines (Hermann-Kleiter and Baier, 
2010). In contrast, ILC2s lack antigen receptors and instead 
integrate numerous locally produced signals to drive cytokine 
production. We hypothesize that in doing so, ILC2s respond 
to perturbations in tissue homeostasis that are common to the 
diverse set of type 2 agonists (von Moltke and Locksley, 2014). 
To date, most studies have focused on the ILC2-activating 
cytokines thymic stromal lymphopoietin, IL-33, and IL-25, of 
which IL-33 is particularly important in the lung (Barlow et 
al., 2013). More recently, the TNF family cytokine TL1A was 
also implicated in ILC2 activation (Yu et al., 2014). Notably, 
although these signals can activate AP-1 and NF-κB (Parnet 
et al., 1996; Brint et al., 2002), none have been linked to rapid 
cytosolic Ca2+ flux. Therefore, whether calcineurin and NFAT 
contribute to ILC2 activation remains an open question.
Group 2 innate lymphoid cells (ILc2s) and type 2 helper t cells (th2 cells) are the primary source of interleukin 5 (IL-5) and 
IL-13 during type 2 (allergic) inflammation in the lung. In th2 cells, t cell receptor (tcr) signaling activates the transcription 
factors nuclear factor of activated t cells (nFAt), nuclear factor κB (nF-κB), and activator protein 1 (AP-1) to induce type 2 
cytokines. ILc2s lack a tcr and respond instead to locally produced cytokines such as IL-33. Although IL-33 induces AP-1 and 
nF-κB, nFAt signaling has not been described in ILc2s. In this study, we report a nonredundant nFAt-dependent role for 
lipid-derived leukotrienes (Lts) in the activation of lung ILc2s. using cytokine reporter and Lt-deficient mice, we find that 
complete disruption of Lt signaling markedly diminishes ILc2 activation and downstream responses during type 2 inflamma-
tion. type 2 responses are equivalently attenuated in IL-33– and Lt-deficient mice, and optimal ILc2 activation reflects potent 
synergy between these pathways. these findings expand our understanding of ILc2 regulation and may have important impli-
cations for the treatment of airways disease.
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Eicosanoids are a family of arachidonic acid metabolites 
that includes the prostaglandins and leukotrienes (LTs). Eico-
sanoids are rapidly synthesized and degraded and are potent 
drivers of inflammation that act on numerous target cells. For 
example, LT signaling induces contraction of smooth muscle, 
chemokine production in mast cells, and permeabilization of 
vasculature. Eicosanoid biosynthesis is initiated by phospho-
lipase A2, which releases arachidonic acid from membrane 
phospholipids (Fig. S1 A). Arachidonic acid then serves as the 
substrate for the cyclooxygenase enzymes, leading to prosta-
glandin production, or for 5-lipoxygenase (ALOX5), which 
catalyzes the first step in all LT synthesis by generating LTA4. 
LTA4 is rapidly converted to LTB4 by LTA4 hydrolase or to 
LTC4 by LTC4 synthase (LTC4S), which conjugates gluta-
thione. Peptidase cleavages convert LTC4 to LTD4 and then 
LTE4, and these three LTs are collectively known as the 
cysteinyl LTs (cysLTs).
Both LTB4 and the cysLTs bind G protein–coupled re-
ceptors. LTB4R1 is the primary LTB4 receptor and in immune 
cells predominantly mediates chemotaxis. LTB4R2 binds LTB4 
with much lower affinity and can respond to other arachidonic 
acid metabolites as well (Yokomizo et al., 2001). CYS LTR1 is 
the best-characterized cysLT receptor, and in transfected cells, 
it exhibits the following ligand preference: LTD4 >> LTC4 > 
LTE4. Like the TCR, CYS LTR1 signals through PLC to in-
duce Ca2+ flux and activate PKC (Peres et al., 2007). CYS LTR2 
expressed in transfected cells binds LTD4 and LTC4 with equal 
affinity, but like CYS LTR1, it does not bind strongly to LTE4 
(Heise et al., 2000; Laidlaw and Boyce, 2012). The high-affinity 
LTE4 receptor was recently identified as OXGR1, also known 
as GPR99 (Kanaoka et al., 2013; Bankova et al., 2016).
The link between LTs and type 2 airway inflammation is 
well established. CYS LTR1 is up-regulated on activated Th2 
cells (Spinozzi et al., 2004; Prinz et al., 2005; Parmentier et 
al., 2012), and both Ltc4s−/− and Ltb4r1−/− mice are protected 
in ovalbumin-induced models of allergic lung inflammation 
(Henderson et al., 1996, 2002; Miyahara et al., 2005; Terawaki 
et al., 2005; Kim et al., 2006). Clinically, LT levels are elevated 
in asthmatic patients (Wardlaw et al., 1989; Hanazawa et al., 
2000), and CYS LTR1 inhibitors provide symptomatic relief, 
particularly for patients with aspirin-exacerbated respiratory 
disease or exercise-induced asthma (Leff et al., 1998; Reiss et 
al., 1998; Dahlén et al., 2002).
Although the roles of both ILC2s and eicosanoids are 
established in type 2 lung inflammation, studies that integrate 
the two remain incomplete. Prostaglandin D2 has been re-
ported as a chemoattractant for mouse and human ILC2s, 
whereas prostacyclin inhibits cytokine production in ILC2s 
(Chang et al., 2014; Xue et al., 2014; Tait Wojno et al., 2015; 
Zhou et al., 2016). Among LTs, studies in human and mouse 
ILC2s demonstrated CYS LTR1 expression and LTD4- 
dependent cytokine induction (Doherty et al., 2013; Xue et 
al., 2014; Pelly et al., 2016). However, analysis of the entire 
set of LTs and their signaling mechanisms in ILC2 activation 
remains incomplete and is therefore the focus of this study.
The analysis of secreted cytokines at the single-cell level 
presents significant technical challenges. Ex vivo restimulation 
and secretion inhibitors are commonly used before intracel-
lular staining, but these approaches rely on antibody sensitiv-
ity and specificity and often reveal the cytokine potential of 
cells rather than their in situ cytokine production. To address 
this problem, we have developed genetically encoded cyto-
kine reporters. Smart13 (Il13Smart/Smart) mice express nonsig-
naling human CD4 (hCD4) from an internal ribosomal entry 
site inserted downstream of the Il13 coding sequence. Surface 
staining for hCD4 therefore allows direct quantification of 
the frequency (percent Smart13+) of IL-13–producing cells 
and the level (Smart13 median fluorescence intensity [MFI]) 
of IL-13 production in each cell directly ex vivo (Liang et al., 
2012). This approach also has the benefit of avoiding fluo- 
rescent reporter proteins with long half-lives that obscure 
subtleties in gene regulation.
Here, we use two models to induce ILC2-driven type 
2 immune responses in the mouse lung. In the first, intra-
nasal delivery of chitin induces an acute, short-lived, type 2 
response driven entirely by innate immune cells, particularly 
ILC2s (Van Dyken et al., 2014). In the second, the intestinal 
helminth Nippostrongylus brasiliensis briefly transits through 
the lung during the first 1–2 d after infection, inducing a 
sustained type 2 response involving both ILC2s and adaptive 
cells. By combining the Smart13 reporter allele with LT syn-
thesis and/or receptor knockout alleles, we dissect the role of 
LT signaling in ILC2 activation in the lung.
resuLts And dIscussIon
Lts are sufficient to activate ILc2s in vitro and in vivo
To assess the complete LT-sensing potential of lung ILC2s, 
we performed quantitative RT-PCR on sorted ILC2s (lin-
eage−;THY1.2+;IL-33R+; Fig. S2, A and B). Indeed, Cysltr1 
and Ltb4r1 were expressed much higher in ILC2s than in 
CD4+ cells and at levels equal to or higher than in blood eo-
sinophils (Fig. 1 a). Expression of Cysltr2 was low in all three 
cell populations tested, whereas Ltb4r2 and the LTE4 receptor 
Oxgr1 were undetectable.
To test the expressed receptors functionally, we sorted 
ILC2s from the lungs of Smart13 reporter mice crossed to 
mice deficient in specific LT receptors, rested them overnight 
in IL-7 to ensure viability, and stimulated them for 6 h, a time 
frame that limited variability from agonist stability, cell sur-
vival, and cell replication (Fig. 1 b, Fig. S2 C, and Fig. S3 A). 
In this assay, LTs rapidly induced IL-13 production in ILC2s 
with the following hierarchy: LTC4 > LTD4 >> LTB4 > LTE4 
(Fig. 1, c and d). The greater potency of LTC4 was particularly 
apparent in the Smart13 MFI, demonstrating that although 
LTD4 and LTC4 activate a similar number of cells, each 
LTC4-activated cell makes more IL-13. Given its prominent 
role in chemotaxis, the ability of LTB4 to induce any cytokine 
production in ILC2s was notable but is perhaps explained by 
its ability to couple with the α-q G protein (Peres et al., 2007). 
As expected, the activity of LTC4 and LTD4 was completely 
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dependent on CYS LTR1, whereas LTB4 required LTB4R1 
(Fig. 1, e and f). Consistent with its low expression level, we 
could not detect any role for CYS LTR2 using this assay.
To confirm our findings in vivo, we treated Smart13 re-
porter mice intranasally with LTs. Here too, LTC4 and LTD4 
activated ILC2s by 6 h after treatment, and this was accom-
panied by accumulation of IL-5 protein in the bronchoal-
veolar lavage (BAL; Fig. S3 B and Fig. 1, g and h). However, 
unlike in vitro, LTE4 did activate ILC2s in vivo, whereas at 
this dose, activation of ILC2s by LTB4 alone was negligible 
in vivo. Collectively, these findings demonstrate that LTs are 
individually sufficient to induce at least modest cytokine pro-
duction in ILC2s, although LTE4 can do so only in vivo and 
likely requires an intermediate cell, possibly an epithelial cell 
(Bankova et al., 2016). In contrast to a previous study using 
cells other than ILC2s (Lynch et al., 1999), we found that 
LTC4 signaling through CYS LTR1 was more potent than 
LTD4. In vivo, LTC4 is rapidly hydrolyzed to LTD4 and then 
LTE4; perhaps this happened in our tissue culture media as 
well, providing ILC2s with successive stimulation by LTC4, 
LTD4, and/or LTE4. Alternatively, ILC2s may encode a novel 
LTC4- and CYS LTR1-dependent signaling pathway, perhaps 
requiring additional receptors.
Lts are largely dispensable for ILc2 homeostasis
To test the necessity of LTs in ILC2 activation, we crossed 
receptor (Cysltr1, Cysltr2, Ltb4r1) and synthase (Alox5, Ltc4s) 
knockout mice to Smart13 reporter mice. We also generated 
Ltc4s;Ltb4r1 double knockout mice to control for shunting 
of excess arachidonic acid into the cyclooxygenase pathway 
in Alox5−/− animals. The development and seeding of ILC2s 
to the lung were normal, and IL-13 production was negligi-
ble in these mice under resting conditions, with the exception 
of Ltc4s−/− mice, discussed in the next paragraph (Fig. 2, a and 
b). Furthermore, ILC2s from Alox5−/− and Ltb4r1;Ltc4s−/− 
mice remained fully responsive to IL-33, LTC4, and LTD4 
(Fig. 2, c–f). As expected, tissue-resident eosinophils were ab-
sent in the resting mouse lungs.
Interestingly, in Ltc4s−/− mice, we noted a trend toward 
more ILC2s and a small but significant increase in basal IL-13 
production (Fig. 2, a and b). These results suggest mild ILC2 
activation in Ltc4s−/− mice, perhaps resulting from shunting 
of excess LTA4 into LTB4 production, as the activation phe-
notype is eliminated in Ltb4r1;Ltc4s doubly deficient mice.
LtB4 and cysLts cooperate to activate ILc2s during type 2 
inflammation in the lung
To test the role of LTs during type 2 lung inflammation, 
we used chitin or N. brasiliensis. 8 h after chitin challenge, 
a fraction of ILC2s in wild-type mice became Smart13+; 
this response was intact in Ltb4r1−/− and Cysltr2−/− mice 
and only mildly reduced in Cysltr1−/− and Ltc4s−/− mice 
(Fig.  3  a), with the caveat that some ILC2s in Ltc4s−/− 
mice were activated before treatment (Fig.  2  b). However, 
Figure 1. Lts are sufficient to rapidly ac-
tivate lung ILc2s. (A) Gene expression mea-
sured by quantitative RT-PCR on cells sorted 
from lungs (CD4 and ILC2) or blood (eosino-
phils) of naive mice. (B) Experimental workflow 
for in vitro ILC2 stimulation assay. (C–F) Fre-
quency (C and E) and MFI (D and F) of Smart13 
reporter–positive lung ILC2s sorted from naive 
wild-type (C and D) or the indicated (E and 
F) mice and treated in vitro for 6 h with the 
indicated LTs. (C and D) Four 10-fold dilutions 
from 100 to 0.1 nM are shown. (E and F) 10 
nM of the indicated LTs. (G and H) Frequency 
of Smart13 reporter–positive ILC2s in lungs 
(G) and amount of IL-5 protein in BAL (H) of 
mice treated for 6 h with 200 ng of the indi-
cated LTs. Data are representative of two ex-
periments (A, E, and F) or pooled from at least 
three experiments (C, D, G, and H). n = 3 tech-
nical replicates (A, E, and F) or at least 3 biolog-
ical replicates (C and D) or biological replicates 
as shown (G and H). *, P < 0.05; **, P < 0.01; 
***, P < 0.001 (compared with PBS by one-way 
ANO VA). Data are means ± SEM. bg, background.
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when LT signaling was completely disrupted (Alox5−/− or 
Ltc4s;Ltb4r1−/−), ILC2 activation was nearly absent. To as-
sess whether this early requirement for LTs was maintained 
during adaptive type 2 responses, we examined lungs 7 d 
after N. brasiliensis infection. We again observed some im-
pact from the loss of cysLT generation or function alone, 
but the loss of both cysLT generation and LTB4R1 func-
tion had much more profound effects. There was a par-
tial decrease in ILC2 accumulation in Alox5−/− and 
Ltc4s;Ltb4r1−/− mice (Fig. 3 b), and IL-13 production was 
nearly absent in those cells that were present, as both the 
frequency of Smart13+ ILC2s and their MFI of Smart13 
was near background levels (Fig. 3, c and d).
Infection by N. brasiliensis leads to eosinophil accumula-
tion and hemorrhage during larval migration through the lung, 
the latter of which can be detected by the presence of blood 
in the BAL. In wild-type mice, the BAL is free of blood by 7 d 
after infection, but in the absence of signaling through IL-4RA 
(required for both IL-4 and IL-13), hemorrhage is more severe 
and prolonged, perhaps because of a loss of type 2–dependent 
tissue repair (Chen et al., 2012). Therefore, both the absence 
of eosinophilia in Alox5−/− and Ltc4s;Ltb4r1−/− mice and the 
presence of blood in the BAL of Alox5−/− mice 7 d after infec-
tion provide in vivo evidence of defective ILC2-mediated type 
2 immune responses in the absence of LT signaling (Fig. 3, e–g).
Activation of ILC2s by LTC4 and LTD4 appears com-
pletely CYS LTR1 dependent, but the response to LTE4 in vivo 
is likely CYS LTR1 independent, which may in part explain 
why ILC2 activation is only partially reduced in Cysltr1−/− 
mice. LTE4 signaling is absent in Ltc4s−/− mice, but it is difficult 
to interpret results in this background given the homeostatic 
activation we observed. However, most notably, the profound 
defects revealed in Alox5−/− and Ltc4s;Ltb4r1−/− mice sug-
gest that both cysLT and LTB4 signaling contribute to ILC2 
activation in vivo. This is perhaps surprising given the modest 
effects observed after 6-h stimulation with LTB4 in vitro and in 
vivo. We speculate that LTB4 provides a weak but more durable 
stimulus for ILC2s or that the well characterized chemotactic 
activity of LTB4 helps to position ILC2s near sources of cysLT.
It should be noted that we cannot rule out the possi-
bility that other LT-responsive cells contribute to ILC2 acti-
vation in vivo. If tools for selective targeting of LT receptors 
in ILC2s become available, it will be interesting to assess the 
extent to which the phenotypes we observed result from 
ILC2-intrinsic LT signaling.
cysLt and IL-33 signaling are nonredundant in ILc2s
A previous study identified IL-33 as a critical signal for ILC2 
activation in the lung and demonstrated substantial protection 
from type 2 inflammation in IL-33–deficient mice (Barlow et 
al., 2013). However, these findings do not preclude the exis-
tence of nonredundant signals that are also required for ILC2 
activation. LTs represent such a nonredundant signal, as BAL 
levels of IL-13 and IL-5, tissue eosinophilia, and ILC2 expan-
sion were all equivalently reduced in the lungs of Il33r−/−, 
Alox5−/−, and Ltb4r1;Ltc4s−/− mice 7 d after N. brasilien-
sis infection (Fig. 4, a–d). These defects were not caused by 
changes in expression of Cysltr1 or Il33r; a modest decrease 
in Ltb4r1 expression is also unlikely to account for the atten-
uated inflammation (Fig. 4, e–g).
To better understand how IL-33 and LTC4 interact to 
activate ILC2s in vivo, we first compared the two agonists in 
vitro. To avoid using anti–IL-33 receptor antibody, we gener-
ated Arg1eYFP/eYFP;Il13Smart/Smart mice and sorted ILC2s using 
the previously characterized Arginase1 marker (Fig. S2, D and 
E; Bando et al., 2013). We found that although IL-33 activates 
ILC2s across a wider range of concentrations, LTC4 achieves greater 
maximal ILC2 activation than IL-33 at this 6-h time point (Fig. 4, h 
Figure 2. Lung ILc2 homeostasis is largely intact in the absence of 
Lts. (A and B) Number of ILC2s (A) and frequency of Smart13 reporter–
positive ILC2s (B) in the lungs of naive mice of the indicated genotypes. 
(C–F) Frequency (C and E) and MFI (D and F) of Smart13 reporter–positive 
lung ILC2s sorted from naive mice of the indicated genotypes and treated 
in vitro for 6 h with 10 nM of the indicated LTs (C and D) or 10 ng/ml IL-33 
(E and F). Data are pooled from at least three experiments (A and B) or 
representative of two experiments (C–F). n = 3 technical replicates (C–F) or 
biological replicates as shown (A and B). **, P < 0.01 (compared with WT[B6] 
by one-way ANO VA). One high Ltc4s−/− outlier was excluded from B by 
Grubb’s test (P < 0.01). Data are means ± SEM. bg, background.
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and i). Because the availability of Arg1eYFP/eYFP;Il13Smart/Smart mice 
was limited, we also confirmed that ILC2s sorted using anti–
IL-33 receptor antibody respond normally to IL-33 (Fig. 4, j 
and k). Next, we compared ILC2 activation by LTC4 and 
IL-33 across a 12-h time course and found strikingly different 
kinetics (Fig. 4, l–n). LTC4 rapidly activated ILC2s, with cy-
tokine production peaking by 4 h after stimulation. In con-
trast, IL-33 was a weaker agonist for the first 8  h but 
surpassed LTC4 by 12 h.
cysLt signaling in ILc2s activates nFAt 
and synergizes with IL-33
Given the reported PKC activation and Ca2+ flux downstream 
of CYS LTR1, we examined whether LTC4 might provide 
ILC2s with a signal analogous to the TCR signal that drives cy-
tokine expression in Th2 cells. PMA (a PKC agonist) and ion-
omycin (a Ca2+ ionophore) are routinely used to mimic PLC 
signaling downstream of the TCR. Therefore, it was notable that 
whereas IL-33 enhanced IL-13 production in ILC2s treated 
with these agonists, the addition of LTC4 was either neutral or 
even inhibitory, suggesting that LTC4 and PMA + ionomycin 
share a common signaling pathway, whereas IL-33 and LTC4 
activate ILC2s through different mechanisms (Fig. 5 a).
Signaling through both IL-33R and CYS LTR1 can 
activate NF-κB and PKC (Parnet et al., 1996; Peres et al., 
2007; Loegering and Lennartz, 2011). Consistently, the PKC 
inhibitor sotrastaurin and the NF-κB inhibitor caffeic acid 
phenethyl ester each individually blocked both LTC4- and 
IL-33–mediated ILC2 activation (Fig. 5, b and c). In contrast, 
cytosolic Ca2+ influx occurs only downstream of CYS LTR1, 
and the calcineurin inhibitor cyclosporin A accordingly in-
hibited cytokine production in LTC4- but not IL-33–treated 
ILC2s (Fig. 5, b and c). NFAT, the primary substrate of cal-
cineurin, has not been previously implicated in ILC2 gene 
regulation. However, we detected NFA TC1 and NFA TC2 in 
ILC2s by immunofluorescence and found that LTC4 but not 
IL-33 induced their translocation to the nucleus, as predicted 
by our findings using cyclosporin A (Fig. 5, d–f). Collectively, 
our results demonstrate that the nonredundant role of LTs in 
ILC2 activation is explained at least in part by the selective ca-
pacity of LTC4 signaling to translocate NFAT to the nucleus.
Given the nonredundant nature of IL-33 and LT signal-
ing in ILC2s, we hypothesized that these two ligands might 
synergize to mediate maximal ILC2 activation. Therefore, 
we stimulated ILC2s with suboptimal levels of IL-33, LTC4, 
or LTD4 alone and in combination. As expected, each signal 
Figure 3. Lts are required for lung ILc2 activation during type 
2 inflammation. (A) Frequency of Smart13 reporter–positive ILC2s 
in the lungs of mice of the indicated genotypes treated 8 h with in-
tranasal chitin. (B–E) Mice of the indicated genotypes infected for 7 d 
with N. brasiliensis (Nb) and then analyzed for number of lung ILC2s 
(B), frequency of Smart13 reporter–positive ILC2s (C), MFI of Smart13 
reporter on ILC2s (D), and number of lung eosinophils (E). (F) BAL 
from mice of the indicated genotypes infected 7 d with N. brasiliensis. 
(G) OD420 of BAL in F to quantify red blood cell infiltrate. Data are 
representative of two experiments (F) or pooled from two (G) or at 
least three experiments (A–E). n = biological replicates as shown. *, P 
< 0.05; **, P < 0.01; ***, P < 0.001 (compared with treated WT[B6] by 
one-way ANO VA). Data are means ± SEM.
ILC2 activation by leukotrienes | von Moltke et al.32
alone induced only minimal ILC2 activation (Fig. 5 g). How-
ever, when IL-33 was combined with LTC4 or LTD4, ILC2 
activation was not just additive but potently synergistic. This 
synergy was also evident in vivo. The combination of low-
dose IL-33 and LTC4 given intranasally induced Smart13 in 
>60% of lung ILC2s in just 6 h, and each cell produced high 
levels of cytokines, as assessed by Smart13 MFI and accumu-
lation of IL-5 and IL-13 in the BAL (Fig. 5, h–k).
concluding remarks
In summary, our findings demonstrate a critical, nonredun-
dant role for LTs in ILC2 activation, provide the first report 
of NFAT signaling in these cells, and suggest that ILC2s in-
tegrate multiple inputs using pathways analogous to those 
downstream of the TCR. Optimal ILC2 activation reflects 
the synergy between LT-dependent NFAT activation, IL-33–
dependent AP-1 and NF-kB activation, and perhaps also 
STAT5 signaling downstream of thymic stromal lympho-
poietin and/or IL-25. As the only NFAT-activating signal 
identified in ILC2s to date, LTs perform a nonredundant 
function in ILC2s and warrant closer attention in other set-
tings where ILC2s are important.
Our findings may also have implications for other ILC 
subsets. ILC2s represent the dominant ILC population in 
the resting lung, whereas ILC1 and ILC3 populations have 
not been well characterized in this setting. We performed 
quantitative RT-PCR to compare sorted lung ILC2s (lin-
eage−;Thy1.2+;IL-33R+) with other ILCs in the lung 
(lineage−;Thy1.2+;IL-33R−). As expected, we found that 
the ILC2-specific transcription factor Gata3 is enriched in 
IL-33R+ cells, whereas Tbet and Rorc, which are required 
for ILC1s and ILC3s, respectively, are detected almost exclu-
sively in IL-33R− cells (Fig. 5 l). Compared with ILC2s, and 
consistent with intestinal ILC analysis by the Immunological 
Figure 4. IL-33 and Lts are nonredundant and signal with different kinetics in lung ILc2s. (A–D) IL-13 (A) or IL-5 (B) protein in the BAL or number 
of eosinophils (C) or ILC2s (D) in the lungs of the indicated mice infected 7 d with N. brasiliensis. (E–G) Expression of Il33r (E), Cysltr1 (F), or Ltb4r1 (G) mea-
sured by quantitative RT-PCR in ILC2s sorted from naive lungs of the indicated mice. (H and I) Frequency (H) or MFI (I) of Smart13 reporter–positive ILC2s 
sorted from the lungs of Arg1Yarg/Yarg;Il13Smart/Smart mice and treated in vitro for 6 h with IL-33 or LTC4, as indicated. Four 10-fold dilutions from 100 nM (LTC4) 
and 100 ng/ml (IL-33) are shown. (J and K) Frequency (J) or MFI (K) of Smart13 reporter–positive ILC2s sorted from lungs of Arg1Yarg/Yarg;Il13Smart/Smart mice 
with or without anti–IL-33R antibody, as indicated. Cells were treated 6 h in vitro with 10 nM LTC4 or 10 ng/ml IL-33. (L and M) MFI (L) or frequency (M) of 
the Smart13 reporter on lung ILC2s sorted from IL13Smart/Smart mice and treated in vitro for the indicated times with 10 nM LTC4 or 10 ng/ml IL-33. (N) IL-5 
protein in the supernatants of cells in L and M. The data shown are pooled from two experiments (A–G) or representative of two experiments (H–N). n = 3 
technical replicates (H–N) or biological replicates as shown (A–G). *, P < 0.05; **, P < 0.01; ***, P < 0.001 (compared with WT[B6] by one-way ANO VA). One 
high WT(B6) outlier was excluded from C by Grubb’s test (P < 0.01). Data are means ± SEM. bg, background.
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Genome Consortium, these IL-33R− lung ILCs expressed 
somewhat lower levels of Cysltr1 and Ltb4r1 and somewhat 
higher levels of Nfat genes than lung ILC2s (Fig. 5, m and n). 
Other ILC subsets may therefore also rely on NFAT signaling 
for cytokine induction, and LT signaling may contribute to its 
activation. It will be interesting to determine whether optimal 
activation of ILC1s and ILC3s also results from an integration 
of multiple signals, analogous to our findings in ILC2s.
To our knowledge, this is the first study to demonstrate 
cooperative functions for LTB4 and cysLTs in the induction 
of cytokine expression, which has important implications for 
clinical practice. Currently, most therapies targeting LTs rely 
Figure 5. nFAt-dependent Ltc4 signaling 
synergizes with IL-33 for optimal ILc2 ac-
tivation. (A) MFI of Smart13 reporter on ILC2s 
sorted from lungs of IL13Smart/Smart mice and 
treated 6 h in vitro with 10 nM LTC4, 10 ng/ml 
IL-33, 30 ng/ml PMA, and/or 500 ng/ml iono-
mycin (Iono), as indicated. (B and C) Frequency 
(B) or MFI (C) of Smart13 reporter–positive 
ILC2s sorted from lungs of IL13Smart/Smart mice 
and treated in vitro for 30 min with 10  µM 
sotrastaurin, 100  µM caffeic acid phenethyl 
ester (CAPE), or 100 nM cyclosporine A (Cyclo 
A) as indicated, followed by 6-h treatment 
with 10 nM LTC4 or 10 ng/ml IL-33 in the 
presence of the indicated inhibitors. (D and E) 
Fluorescence microscopy of ILC2s sorted from 
lungs of WT(B6) mice and treated 30 min with 
cyclosporine A (CSA) as indicated followed by 
90-min treatment with 100 nM LTC4, 100 ng/
ml IL-33, 30 ng/ml PMA, and/or 500 ng/ml ion-
omycin, as indicated. Cells were stained with 
anti-NFA TC1 (D) or anti-NFA TC2 (E) and DAPI 
(blue). White asterisks indicate nuclear local-
ization of NFAT. Bars, 10 µm. (F) Quantification 
of cells in E with nuclear localization of NFA 
TC2. At least 40 cells were counted for each 
condition. P + I, PMA + ionomycin. (G) MFI 
of the Smart13 reporter on ILC2s sorted from 
the lungs of IL13Smart/Smart mice and treated in 
vitro for 6 h with the indicated combinations 
of IL-33 with LTC4 or LTD4. (H–K) Il13Smart/Smart 
mice treated 6 h with 50 ng IL-33 or LTC4 given 
intranasally alone or in combination and ana-
lyzed for frequency (H) or MFI (I) of Smart13 
reporter–positive ILC2s in lungs or IL-5 (J) or 
IL-13 (K) in the BAL. (L–N) Quantitative RT-
PCR analysis of the indicated genes in ILC2s 
(lineage−;Thy1.2+;IL-33R+) or other ILCs (lin-
eage−;Thy1.2+;IL-33R−) sorted from the lungs 
of naive WT(B6) mice. (O) Expression of Il5 
measured by quantitative RT-PCR in ILC2s 
sorted from naive lungs of the indicated mice. 
The data shown are pooled from three (A–C 
and H–K) or two (L–N) experiments or are rep-
resentative of two (D–F and O) or three (G) ex-
periments. n = 3 (A–C), 2 (F) or 1 (G) technical 
replicates, or 5–6 (L–N) or biological replicates 
as shown (F, H–K, and O). #, not detected. *, P 
< 0.05; **, P < 0.01; ***, P < 0.001 (compared 
with PBS by one-way ANO VA [H–K and O] or 
pairwise comparison by Student’s t test [L–N]). 
Data are means ± SEM. bg, background.
ILC2 activation by leukotrienes | von Moltke et al.34
on the potent CYS LTR1 inhibitors montelukast, pranlukast, 
and zafirlukast, which bind their targets with nanomolar affin-
ity (Lynch et al., 1999). Zileuton, the only approved 5-lipoxy-
genase inhibitor, requires 4× daily dosing and is less frequently 
prescribed. However, our results suggest that a renewed focus 
on 5-lipoxygenase inhibitors (or LTB4 inhibitors in combina-
tion with CYS LTR1 inhibitors) may be warranted. Indeed, 
there is evidence that despite achieving only partial inhibition 
of systemic LT levels, zileuton may be particularly valuable in 
treating nasal dysfunction and bronchial hyperresponsiveness, 
the latter of which is often refractory to treatment with CYS 
LTR1 inhibitors alone (Dahlén et al., 1998).
The distinct kinetics and effective doses of IL-33 and 
LTC4 lead us to propose a model in which these two ag-
onists serve qualitatively different functions in ILC2 activa-
tion. IL-33, which remains active at 0.1 ng/ml (Fig. 4 h), may 
be important not just during inflammation, but also during 
homeostasis to provide a tonic signal that maintains ILC2s 
in a primed state. However, LTC4 is rapidly synthesized and 
degraded and therefore likely represents a more labile sig-
nal for rapid cytokine induction during inflammation. Con-
sistent with this model, the constitutive production of IL-5 
by ILC2s in naive mice is strongly IL-33 dependent but LT 
independent (Fig.  5  o). Interestingly, as Th2 cells mature 
in the tissue, their cytokine production becomes TCR in-
dependent, whereas IL-33R and CYL STR1 are both up- 
regulated (Prinz et al., 2005; Parmentier et al., 2012; Guo et 
al., 2015; Van Dyken et al., 2016). Perhaps IL-33–LTC4 syn-
ergy is an innate substitute for TCR signaling in ILC2s and 
these TCR-independent effector Th2 cells.
The results presented here demonstrate a critical, nonre-
dundant role for LTs in the activation of ILC2s and suggest 
several avenues for further research. In particular, it will be 
important to identify the cellular sources of LTs that act on 
ILC2s and to understand the upstream signals that drive LT 
synthesis. Given that IL-33 release has been linked to me-
chanical stretch or damage of tissue (Moussion et al., 2008; 
Kakkar et al., 2012), it will be interesting to determine 
whether LTs are similarly induced by tissue perturbation, 
which would be consistent with our model that ILC2s in-
tegrate multiple host-derived signals to assess the status of 
the surrounding tissue.
MAterIALs And Methods
Mice
Mice were maintained in the University of California, San 
Francisco specific pathogen–free animal facility in accordance 
with the guidelines established by the Institutional Animal 
Care and Use Committee and Laboratory Animal Resource 
Center. Mice aged 6–12 wk were used for all experiments. 
Mice were age- and sex-matched in figures displaying a single 
representative experiment. Pooled results include both male 
and female mice of varying ages. Unless otherwise noted, all 
mice used in these studies were homozygous for the Smart13 
reporter allele (Il13Smart/Smart), which was generated as previ-
ously described (Liang et al., 2012). In brief, a cDNA fragment 
encoding truncated hCD4 (with a point mutation that results 
in the substitution of isoleucine for phenylalanine at posi-
tion 43 of the protein, to abrogate binding of mouse major 
histocompatibility complex class II) preceded by an internal 
ribosomal entry sequence was introduced between the stop 
codon of Il13 and the 3′ untranslated region. Smart13 mice 
were generated on a BALB/c background and backcrossed for 
at least eight generations to C57BL/6J. BALB/c.Arg1eYFP/eYFP 
mice were generated as previously described (Reese et al., 
2007) and backcrossed to C57BL/6J for at least eight gen-
erations. Alox5−/− (B6.129S2-Alox5tm1Fun/J; 004155) and 
Ltb4r1−/− (B6.129S4-Ltb4r1tm1Adl/J; 008102) mice were pur-
chased from The Jackson Laboratory. B6.Cysltr1−/−, B6.Cys-
ltr2−/−, and B6.Ltc4s−/− mice were generated as previously 
described (Kanaoka et al., 2001; Maekawa et al., 2002; Beller 
et al., 2004). B6.Ltb4r1−/−;Ltc4s−/− mice were bred in house.
In vivo treatments
Pure chitin beads (New England Biolabs, Inc.) ranging from 
50 to 70 µm in diameter were prepared by size filtration 
through nylon mesh, washed, and reconstituted in sterile PBS 
(Ca2+ and Mg2+ free) at a final concentration of 105 chitin 
beads/ml. Mice were briefly anesthetized with isoflurane, and 
50 µl of this suspension (5,000 beads) was aspirated by in-
tranasal administration, followed by euthanasia and analysis 
at various time points after instillation. Separately, mice were 
infected subcutaneously with 500 third-stage N. brasiliensis 
larvae, which were raised and maintained as previously de-
scribed (Liang et al., 2012). LTB4, LTC4, LTD4, LTE4 (Cayman 
Chemicals), and IL-33 (R&D Systems) were diluted in ster-
ile PBS and delivered intranasally to isoflurane-anesthetized 
mice in a final volume of 50 µl.
tissue preparation
For lung analysis, mice were euthanized, and BAL was col-
lected in 1 ml PBS, if necessary. Then, the lungs were perfused 
through the heart with 10 ml PBS and harvested. Single-cell 
suspensions were prepared with an automated tissue disso-
ciator (gentleMACS; Miltenyi Biotec), running program 
lung_01 followed by incubation for 35 min at 37° C in HBSS 
(Ca2+and Mg2+ free) containing 0.2 mg/ml Liberase (Roche) 
and 25 µg/ml DNase I (Roche), and then running gentle-
MACS program lung_02. The tissue was further dispersed by 
passing through 70-mm nylon filters, washed, and subjected 
to red blood cell lysis (PharmLyse; BD) before final suspen-
sion in PBS with 3% fetal calf serum. For eosinophil sort-
ing, 1–2 ml of blood was subjected to red blood cell lysis in 
PharmLyse for 5 min before washing and antibody staining.
Flow cytometry and cell sorting
Single-cell suspensions prepared as described in the Tissue 
preparation section were incubated with anti-CD16 and CD32 
monoclonal antibodies (University of California, San Fran-
cisco Antibody Core Facility) for 10 min at 4°C. The cells were 
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stained with antibodies to surface markers for 20 min at 4°C 
followed by DAPI (Roche) for dead cell exclusion. See Fig. S1 
for a list of antibodies used in this study. CountBright Absolute 
Counting Beads (Thermo Fisher Scientific) were used accord-
ing to the manufacturer’s instructions to determine total cell 
numbers in each sample. Samples were analyzed on a Fortessa 
flow cytometer (BD) with five lasers (355 nm, 405 nm, 488 nm, 
561 nm, and 640 nm) or sorted on a MoFlo XDP cell sorter 
(Beckman Coulter). Samples were gated by forward and side 
scatter to exclude debris, forward scatter width by forward scat-
ter area–gated to select single cells, and gated to exclude DAPI+ 
dead cells. Data were analyzed with FlowJo 10 (Tree Star).
In vitro ILc2 culture and analysis
ILC2s were sorted from lungs of naive Il13Smart/Smart mice, 
as described in the Flow cytometry and cell sorting section. 
Basal media for ILC2 culture was high-glucose DMEM sup-
plemented as follows: 4.5 g/L glucose, 0.584 g/L l-glutamine, 
3.7 g/L NaHCO3, 1× nonessential amino acids, 1× minimal 
essential vitamins, 0.116 g/L l-arginine HCl, 0.036 g/L l-as-
paragine, 0.006 g/L folic acid, 10% FBS, 100 mg/ml strep-
tomycin, 100 U/ml penicillin, 10  mM Hepes, 1  mM Na 
pyruvate, 100 µM 2-ME, and 2 mM l-glutamine. Cells were 
plated at 4,000–5,000 cells/well in 96-well plates and incu-
bated overnight in 10 ng/ml IL-7 (R&D Systems). The next 
morning, media was replaced with fresh media containing 
10 ng/ml IL-7 and the indicated LT (Cayman Chemical) or 
cytokine (R&D Systems) agonists. The following chemical 
agonists and inhibitors were used where indicated: 30 ng/
ml PMA (Sigma-Aldrich), 500 ng/ml ionomycin (Sigma- 
Aldrich), 10  µM sotrastaurin (Cayman Chemical), 100  µM 
caffeic acid phenethyl ester (Cayman Chemical), and 100 nM 
cyclosporin A (Cayman Chemical). After 6-h incubation at 
37°C, cells were stained with 1 µl/well of PE-conjugated anti- 
hCD4 for 30 min on ice. Cells were washed, resuspended in 
DAPI, and analyzed on a flow cytometer (Dual Fortessa; BD).
cytokine quantification
Levels of IL-5 and/or IL-13 in BAL or cell culture su-
pernatant were measured using Cytokine Bead Array 
Enhanced Sensitivity Flex Sets (BD) according to the 
manufacturer’s protocol.
Quantitative rt-Pcr
ILCs and CD4+ cells were sorted from the lungs and eo-
sinophils from the blood of naive mice, as described in the 
Flow cytometry and cell sorting section. RNA was isolated 
using the Micro Plus RNeasy kit (QIA GEN) and subjected 
to reverse transcription using SuperScript Vilo Master Mix 
(Thermo Fisher Scientific). The resulting cDNA was used 
as a template for quantitative PCR with the Power SYBR 
green reagent on a StepOnePlus cycler (Applied Bio-
systems). Transcripts were normalized to Rps17 (40S ri-
bosomal protein S17) expression. See Fig. S1 for a list of 
primers used in this study.
nFAt imaging
ILC2s were sorted from the lungs of naive wild-type mice 
and cultured overnight in 10 ng/ml IL-7, as described in the 
In vitro ILC2 culture and analysis section. The next morning, 
cells were treated for 90 min as indicated and affixed to slides 
by Cytospin followed by 5 min in ice-cold methanol. Slides 
were blocked for 30 min with 10% goat serum and then in-
cubated 60 min with 1:100 polyclonal rabbit anti-NFA TC2 
(NFAT1; clone D43B1; Cell Signaling Technology) or 1:50 
with Alexa Fluor 488 anti-NFA TC1 (NFAT2; clone 7A6; Bi-
oLegend). For NFA TC2 staining, cells were next incubated 40 
min with Alexa Fluor 555 goat anti–rabbit IgG Fc (Thermo 
Fisher Scientific). All cells were counterstained for 5 min with 
DAPI. Images were acquired with a camera (AxioCam HR) 
on an upright microscope (AxioImagerM2; ZEI SS).
statistical analysis
All experiments were performed using randomly assigned 
mice without investigator blinding. Where noted in the fig-
ures, statistical significance was calculated using one-way 
ANO VA with Dunnett’s correction or two-tailed Students's 
t test. All statistical analysis was performed using Prism 6 
(GraphPad Software). Figures display means ± SEM.
online supplemental material
Fig. S1 shows the LT biosynthesis pathways and lists an-
tibodies and primers used in this study. Figs. S2 and S3 
show gating strategies.
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